News
CNTA
39.53
-0.10%
-0.04
Weekly Report: what happened at CNTA last week (0406-0410)?
Weekly Report · 1d ago
Centessa downgraded to Hold from Buy at Truist
TipRanks · 1d ago
Centessa is the top performing foreign healthcare stock YTD
Seeking Alpha · 6d ago
Looks Like M&A Week in 3 Different Sectors
The Motley Fool · 6d ago
Weekly Report: what happened at CNTA last week (0330-0403)?
Weekly Report · 04/06 10:27
The Next Big AI Winner Might Not Be a Tech Company
Barchart · 04/04 10:30
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy
Benzinga · 04/03 14:35
Biotech Is Holding Steady In 2026
Seeking Alpha · 04/02 16:49
This Akamai Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Benzinga · 04/02 15:34
Centessa Pharmaceuticals Cut to Neutral From Buy by Guggenheim
Dow Jones · 04/02 13:56
Guggenheim Downgrades Centessa Pharmaceuticals to Neutral
Benzinga · 04/02 13:47
Centessa Pharmaceuticals Price Target Raised to $40.00/Share From $36.00 by Leerink Partners
Dow Jones · 04/01 20:38
Centessa Pharmaceuticals Cut to Market Perform From Outperform by Leerink Partners
Dow Jones · 04/01 20:38
Leerink Partners Downgrades Centessa Pharmaceuticals to Market Perform, Raises Price Target to $40
Benzinga · 04/01 20:28
Centessa downgraded to Neutral from Buy at Guggenheim
TipRanks · 04/01 16:00
Centessa Pharmaceuticals Agrees To Eli Lilly Acquisition At 40% Premium
Benzinga · 04/01 14:43
Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
TipRanks · 04/01 13:51
Centessa downgraded to Market Perform from Outperform at LifeSci Capital
TipRanks · 04/01 11:52
Centessa Pharmaceuticals Reaches Analyst Target Price
NASDAQ · 04/01 10:58
Centessa downgraded to Market Perform from Outperform at Leerink
TipRanks · 04/01 10:17
More
Webull provides a variety of real-time CNTA stock news. You can receive the latest news about Centessa Pharmaceuticals Plc through multiple platforms. This information may help you make smarter investment decisions.
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.